Rigel Pharmaceuticals, Inc. (RIGL) stock has gained 11.04% over the past week and gets a Bullish rating from InvestorsObserver's Sentiment Indicator.
What is Stock Sentiment?
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With RIGL Stock Today?
Rigel Pharmaceuticals, Inc. (RIGL) stock is down -1.9% while the S&P 500 is up 1.02% as of 12:13 PM on Thursday, May 13. RIGL has fallen -$0.07 from the previous closing price of $3.69 on volume of 1,627,765 shares. Over the past year the S&P 500 has gained 43.01% while RIGL is up 91.53%. RIGL lost -$0.08 per share in the over the last 12 months.
To see InvestorsObserver's Sentiment Score for Rigel Pharmaceuticals, Inc. click here.
More About Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Click Here to get the full Stock Score Report on Rigel Pharmaceuticals, Inc. (RIGL) Stock.
